Crescita Therapeutics Inc. (CTX.TO)
| Previous Close | 0.6400 |
| Open | 0.6400 |
| Bid | 0.6400 x 0 |
| Ask | 0.6600 x 0 |
| Day's Range | 0.6400 - 0.6400 |
| 52 Week Range | 0.3600 - 0.7000 |
| Volume | |
| Avg. Volume | 24,414 |
| Market Cap | 12.017M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireCrescita Reports Second Quarter 2024 Results
LAVAL, Quebec, August 07, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2024 ("Q2-2024"). All amounts presented in this press release are in thousands of Canadian dollars ("CAD") unless otherwise noted and are in accordance with International Financial Reporting Standards ("IFRS") as issued by the I
Business WireCrescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
LAVAL, Quebec, July 22, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced the signing of an amendment to its contract manufacturer supply agreement (the "Amended Agreement") with its largest CMO client (the "Client"), a global skin care company. The Amended Agreement expands the existing partnership between Cresc
- Baystreet
Stocks in play: Crescita Therapeutics Inc.
Today announced that it has signed an exclusive Manufacturing and Supply Agreement with a leading Canadian ...
